Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

Mark Pruzan­s­ki spent more than 18 years grow­ing In­ter­cept from a start­up to a com­mer­cial play­er look­ing for a land­mark ap­proval treat­ing NASH. But 19 months af­ter he stepped aside from his wound­ed biotech — af­ter a CRL crushed its ini­tial game plan for NASH — the long­time vet is get­ting up off the biotech board bench and get­ting back in the game, once again quar­ter­back­ing a start­up that has some very fa­mil­iar grand am­bi­tions.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE